9.38
price up icon5.27%   0.47
after-market アフターアワーズ: 9.20 -0.18 -1.92%
loading
前日終値:
$8.91
開ける:
$8.85
24時間の取引高:
1.16M
Relative Volume:
0.60
時価総額:
$619.20M
収益:
$170.44M
当期純損益:
$-193.88M
株価収益率:
-2.4986
EPS:
-3.7541
ネットキャッシュフロー:
$-126.38M
1週間 パフォーマンス:
-21.96%
1か月 パフォーマンス:
-3.60%
6か月 パフォーマンス:
+7.20%
1年 パフォーマンス:
+2.85%
1日の値動き範囲:
Value
$8.61
$9.43
1週間の範囲:
Value
$7.77
$12.08
52週間の値動き範囲:
Value
$5.455
$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1084)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
371
Name
Twitter
@REGENXBIO
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
RGNX icon
RGNX
Regenxbio Inc
9.38 730.11M 170.44M -193.88M -126.38M -3.7541
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
547.29 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
814.79 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,047.10 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
149.66 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
215.44 45.38B 742.00K -1.37B -1.07B -7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2025-02-11 ダウングレード Goldman Buy → Neutral
2025-02-07 再開されました Raymond James Outperform
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
Aug 21, 2026

REGENXBIO (NASDAQ:RGNX) Trading Down 3.9%Should You Sell? - MarketBeat

Aug 21, 2026
pulisher
Aug 17, 2026

RGNX Q2 2026 Earnings: Gene Therapy Developer Posts 626% EPS SurpriseEBITDA Analysis - Vinanet

Aug 17, 2026
pulisher
Aug 17, 2026

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits

Aug 17, 2026
pulisher
Aug 17, 2026

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Aug 17, 2026
pulisher
Aug 15, 2026

Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us

Aug 14, 2026
pulisher
Aug 14, 2026

REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - MarketBeat

Aug 14, 2026
pulisher
Aug 14, 2026

Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - MarketBeat

Aug 14, 2026
pulisher
Aug 13, 2026

REGENXBIO (RGNX) Pulls Back 2.29% to $10.66 — Gene Therapy Play Tests Key SupportPCR Moving Average - Vinanet

Aug 13, 2026
pulisher
Aug 13, 2026

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits

Aug 13, 2026
pulisher
Aug 12, 2026

(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Aug 12, 2026
pulisher
Aug 12, 2026

HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - MarketBeat

Aug 12, 2026
pulisher
Aug 11, 2026

REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha

Aug 11, 2026
pulisher
Aug 10, 2026

H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK

Aug 10, 2026
pulisher
Aug 10, 2026

RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 10, 2026
pulisher
Aug 10, 2026

H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com

Aug 10, 2026
pulisher
Aug 10, 2026

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo

Aug 10, 2026
pulisher
Aug 10, 2026

Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - MarketBeat

Aug 10, 2026
pulisher
Aug 09, 2026

RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 09, 2026
pulisher
Aug 09, 2026

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review

Aug 09, 2026
pulisher
Aug 09, 2026

Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 09, 2026
pulisher
Aug 08, 2026

RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 08, 2026
pulisher
Aug 08, 2026

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail

Aug 08, 2026
pulisher
Aug 08, 2026

REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway - Sahm

Aug 08, 2026
pulisher
Aug 08, 2026

REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Wall Street Zen - MarketBeat

Aug 08, 2026
pulisher
Aug 07, 2026

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says - marketscreener.com

Aug 07, 2026
pulisher
Aug 07, 2026

REGENXBIO (NASDAQ:RGNX) Shares Down 6.1%Here's Why - MarketBeat

Aug 07, 2026
pulisher
Aug 07, 2026

REGENXBIO Price Target Maintained With a $12.00/Share by Barclays - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

Barclays downgrades Regenxbio stock rating on regulatory uncertainty By Investing.com - Investing.com UK

Aug 07, 2026
pulisher
Aug 07, 2026

Barclays Reiterates "Equal Weight" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Aug 07, 2026
pulisher
Aug 07, 2026

Barclays downgrades Regenxbio stock rating on regulatory uncertainty - Investing.com

Aug 07, 2026
pulisher
Aug 07, 2026

Barclays Downgrades REGENXBIO to Equalweight From Overweight, $12 Price Target - marketscreener.com

Aug 07, 2026
pulisher
Aug 07, 2026

REGENXBIO Q2 Earnings Call Highlights - MarketBeat

Aug 07, 2026
pulisher
Aug 07, 2026

Barclays downgrades Regenxbio stock rating on regulatory concerns By Investing.com - Investing.com Australia

Aug 07, 2026
pulisher
Aug 07, 2026

Morgan Stanley Adjusts Price Target on REGENXBIO to $18 From $16, Maintains Overweight Rating - marketscreener.com

Aug 07, 2026
pulisher
Aug 07, 2026

Barclays downgrades Regenxbio stock rating on regulatory concerns - Investing.com

Aug 07, 2026
pulisher
Aug 07, 2026

REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 101% Upside Potential in the Biotech Sector - DirectorsTalk Interviews

Aug 07, 2026
pulisher
Aug 07, 2026

REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS - MarketBeat

Aug 07, 2026
pulisher
Aug 06, 2026

RGNX DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review

Aug 06, 2026
pulisher
Aug 06, 2026

REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket - Investing.com Nigeria

Aug 06, 2026
pulisher
Aug 06, 2026

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Ru - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Form 8K Regenxbio Inc For: 6 August By Investing.com - Investing.com South Africa

Aug 06, 2026
pulisher
Aug 06, 2026

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

RGNX: Milestones in gene therapy pipeline and $310M+ cash position drive outlook through 2027 - tradingview.com

Aug 06, 2026
pulisher
Aug 06, 2026

REGENXBIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 06, 2026
pulisher
Aug 06, 2026

Transcript : REGENXBIO Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com

Aug 06, 2026
pulisher
Aug 06, 2026

REGENXBIO Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com

Aug 06, 2026
pulisher
Aug 06, 2026

Regenxbio: Q2 Earnings Snapshot - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

REGENXBIO Inc. Q2 2026: Revenue $108M, EPS $0.43— 10-Q Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

REGENXBIO Q2 revenue rises to $108 million as RGX-202 BLA nears - Quiver Quantitative

Aug 06, 2026

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Regenxbio Inc (RGNX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
PAKOLA STEVE
Chief Medical Officer
Jul 02 '26
Sale
13.64
2,161
29,476
213,009
PAKOLA STEVE
Chief Medical Officer
Jul 01 '26
Option Exercise
7.86
36,725
288,658
249,734
PAKOLA STEVE
Chief Medical Officer
Jul 01 '26
Sale
12.86
36,725
472,284
213,009
PAKOLA STEVE
Chief Medical Officer
Jun 29 '26
Sale
11.04
19,608
216,472
213,009
$124.39
price up icon 0.40%
$61.80
price down icon 0.43%
$112.56
price down icon 1.31%
$239.00
price down icon 0.45%
ONC ONC
$375.80
price down icon 0.15%
$215.44
price up icon 1.92%
大文字化:     |  ボリューム (24 時間):